BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 18719377)

  • 1. Targeting the eIF4F translation initiation complex for cancer therapy.
    Konicek BW; Dumstorf CA; Graff JR
    Cell Cycle; 2008 Aug; 7(16):2466-71. PubMed ID: 18719377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting eukaryotic translation in mesothelioma cells with an eIF4E-specific antisense oligonucleotide.
    Jacobson BA; Thumma SC; Jay-Dixon J; Patel MR; Dubear Kroening K; Kratzke MG; Etchison RG; Konicek BW; Graff JR; Kratzke RA
    PLoS One; 2013; 8(11):e81669. PubMed ID: 24260583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma.
    Demosthenous C; Han JJ; Stenson MJ; Maurer MJ; Wellik LE; Link B; Hege K; Dogan A; Sotomayor E; Witzig T; Gupta M
    Oncotarget; 2015 Apr; 6(11):9488-501. PubMed ID: 25839159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the eIF4F translation initiation complex: a critical nexus for cancer development.
    Pelletier J; Graff J; Ruggero D; Sonenberg N
    Cancer Res; 2015 Jan; 75(2):250-63. PubMed ID: 25593033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vesicular stomatitis virus infection alters the eIF4F translation initiation complex and causes dephosphorylation of the eIF4E binding protein 4E-BP1.
    Connor JH; Lyles DS
    J Virol; 2002 Oct; 76(20):10177-87. PubMed ID: 12239292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquired Tamoxifen Resistance in MCF-7 Breast Cancer Cells Requires Hyperactivation of eIF4F-Mediated Translation.
    Fagan DH; Fettig LM; Avdulov S; Beckwith H; Peterson MS; Ho YY; Wang F; Polunovsky VA; Yee D
    Horm Cancer; 2017 Aug; 8(4):219-229. PubMed ID: 28577281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eukaryotic translation initiation factor 4F architectural alterations accompany translation initiation factor redistribution in poxvirus-infected cells.
    Walsh D; Arias C; Perez C; Halladin D; Escandon M; Ueda T; Watanabe-Fukunaga R; Fukunaga R; Mohr I
    Mol Cell Biol; 2008 Apr; 28(8):2648-58. PubMed ID: 18250159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the eukaryotic translation initiation factor 4E for cancer therapy.
    Graff JR; Konicek BW; Carter JH; Marcusson EG
    Cancer Res; 2008 Feb; 68(3):631-4. PubMed ID: 18245460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computational inference of eIF4F complex function and structure in human cancers.
    Wu S; Wagner G
    Proc Natl Acad Sci U S A; 2024 Jan; 121(5):e2313589121. PubMed ID: 38266053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eukaryotic translation initiation factor 4E availability controls the switch between cap-dependent and internal ribosomal entry site-mediated translation.
    Svitkin YV; Herdy B; Costa-Mattioli M; Gingras AC; Raught B; Sonenberg N
    Mol Cell Biol; 2005 Dec; 25(23):10556-65. PubMed ID: 16287867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Requirement of the eukaryotic translation initiation factor 4F complex in hepatitis E virus replication.
    Zhou X; Xu L; Wang Y; Wang W; Sprengers D; Metselaar HJ; Peppelenbosch MP; Pan Q
    Antiviral Res; 2015 Dec; 124():11-9. PubMed ID: 26526587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computational inference of eIF4F complex function and structure in human cancers.
    Wu S; Wagner G
    bioRxiv; 2023 Aug; ():. PubMed ID: 37609226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small-molecule inhibition of oncogenic eukaryotic protein translation in mesothelioma cells.
    Chen EZ; Jacobson BA; Patel MR; Okon AM; Li S; Xiong K; Vaidya AJ; Bitterman PB; Wagner CR; Kratzke RA
    Invest New Drugs; 2014 Aug; 32(4):598-603. PubMed ID: 24711125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deep computational analysis details dysregulation of eukaryotic translation initiation complex eIF4F in human cancers.
    Wu S; Wagner G
    Cell Syst; 2021 Sep; 12(9):907-923.e6. PubMed ID: 34358439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toward the mechanism of eIF4F-mediated ribosomal attachment to mammalian capped mRNAs.
    Kumar P; Hellen CU; Pestova TV
    Genes Dev; 2016 Jul; 30(13):1573-88. PubMed ID: 27401559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blocking eukaryotic initiation factor 4F complex formation does not inhibit the mTORC1-dependent activation of protein synthesis in cardiomyocytes.
    Huang BP; Wang Y; Wang X; Wang Z; Proud CG
    Am J Physiol Heart Circ Physiol; 2009 Feb; 296(2):H505-14. PubMed ID: 19074679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. c-Myc and eIF4F constitute a feedforward loop that regulates cell growth: implications for anticancer therapy.
    Lin CJ; Malina A; Pelletier J
    Cancer Res; 2009 Oct; 69(19):7491-4. PubMed ID: 19773439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cap-dependent mRNA translation and the ubiquitin-proteasome system cooperate to promote ERBB2-dependent esophageal cancer phenotype.
    Issaenko OA; Bitterman PB; Polunovsky VA; Dahlberg PS
    Cancer Gene Ther; 2012 Sep; 19(9):609-18. PubMed ID: 22767218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Cap for Every Occasion: Alternative eIF4F Complexes.
    Ho JJD; Lee S
    Trends Biochem Sci; 2016 Oct; 41(10):821-823. PubMed ID: 27283511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Manipulation of the host translation initiation complex eIF4F by DNA viruses.
    Walsh D
    Biochem Soc Trans; 2010 Dec; 38(6):1511-6. PubMed ID: 21118117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.